Loading data for TLSA — first visit, this takes a few seconds.

알림

Tiziana Life Sciences Ltd (TLSA)

NasdaqCM: TLSA · 실시간 가격 · USD

1.14

+0.07 (6.54%)

종가 기준: Aug 20, 2026, 8:00 PM

1.15

+2.68%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

6.54% (1D)

데이터 없음

매수호가	1.09
시가총액	142.53M
매출 (ttm)	n/a
순이익 (ttm)	-18.43M
	0.46
	-0.17
	n/a
	-5.61
P/B (ttm)	14.55
P/S (ttm)	n/a
실적 발표일	n/a

매도호가	1.11
거래량	1,534,502
평균 거래량 (20일)	509,072
시가	1.08
전일 종가	1.07
일중 범위	1.04 - 1.16
52주 범위	0.87 - 2.35
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

TLSA 소개

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic latera...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 20, 2018

직원 수 10

상장 거래소 NasdaqCM

티커 TLSA

웹사이트 https://www.tizianalifesciences.com

전체 기업 정보

재무 실적

2025년 Tiziana Life Sciences Ltd의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -18.43M로, 55.37% 증가했습니다.

재무제표

어닝 서프라이즈

Tiziana Life Sciences Ltd가 Dec 27, 2022에 분기 실적을 발표했습니다:

매출 n/a 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.06 예상치 하회 , 및 -Infinity% 전년 대비 감소.

뉴스

2주 전 · Proactive

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal fo...

1개월 전 · Proactive

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Mul...

2개월 전 · Motley Fool

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

3개월 전 · Proactive

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded a...

3개월 전 · Proactive

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress...

2 페이지 중 1

Tiziana Life Sciences Ltd (TLSA)